The European Glaucoma Prevention Study should be able to better address the clinical question of whether pharmacological reduction of IOP ( by means of dorzolamide ) in ocular hypertension patients at moderate risk for developing primary open-angle glaucoma effectively lowers the incidence of primary open-angle glaucoma .
